HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
carmethizole
RN & structure given in first source; RN given refers to HCl; RN for parent cpd not available 2/89
Also Known As:
1-methyl-2-(methylthio)-4,5-bis(hydroxymethyl)imidazole-bis(N-methylcarbamate)
Networked:
4
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
carmethizole: 4
Related Diseases
1.
Neoplasms (Cancer)
11/12/1993 - "
Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
"
01/01/1992 - "
The therapeutic effect of carmethizole was not route-dependent, as was evidenced by the similar delays observed in tumor growth following i.p.
"
01/01/1992 - "
Carmethizole hydrochloride [1-methyl-2-methylthio-4,5-bis(hydroxymethyl)imidazole-4', 5'-bis(N-methylcarbamate)hydrochloride, NSC 602,668; hereafter called carmethizole] is a new antitumor drug that has shown relatively broad activity in initial evaluations against several murine tumors and human tumor xenografts in vivo.
"
09/01/1991 - "
Carmethizole, Cytoxan, and melphalan were all active and had comparable activity against the HCT-8 and MX-1 human tumor xenografts.
"
09/01/1991 - "
Carmethizole activity was similar to that of melphalan across the murine solid tumor panel, which consisted of B16 melanoma; colon adenocarcinomas 11a, 26, and 36; and the KHT sarcoma.
"
2.
Sarcoma (Soft Tissue Sarcoma)
01/01/1989 - "
The derivative 2i, referred to by the name carmethizole, was also shown to be active against the MX-1 mammary xenograft, the human amelanotic melanoma cell line (LOX) xenograft, the M5076 sarcoma, and L1210 lymphocytic leukemia.
"
09/01/1991 - "
Carmethizole activity was similar to that of melphalan across the murine solid tumor panel, which consisted of B16 melanoma; colon adenocarcinomas 11a, 26, and 36; and the KHT sarcoma.
"
3.
Leukemia
09/01/1991 - "
In vivo, carmethizole was not cross-resistant with 1,3-bis(2-chloroethyl)-1-nitrosourea or Cytoxan as determined by testing against P388 leukemias resistant to the latter 2 agents.
"
01/01/1992 - "
Murine leukemias resistant to vincristine (VCR), amsacrine (AMSA), or methotrexate (MTX) were not cross-resistant to carmethizole.
"
01/01/1992 - "
However, murine leukemias resistant to doxorubicin (ADR), melphalan (L-PAM), cisplatin (DDPt), 1-beta-D-ara-binofuranosylcytosine (ara-C), and 5-fluorouracil (5-FU) were cross-resistant to carmethizole, suggesting that patients who have previously been treated with any of these agents might be less likely to respond to carmethizole than those who have had no opportunity to develop resistance to any of these compounds.
"
4.
Amelanotic Melanoma (Amelanotic Melanomas)
01/01/1989 - "
The derivative 2i, referred to by the name carmethizole, was also shown to be active against the MX-1 mammary xenograft, the human amelanotic melanoma cell line (LOX) xenograft, the M5076 sarcoma, and L1210 lymphocytic leukemia.
"
5.
Experimental Melanoma
09/01/1991 - "
Carmethizole activity was similar to that of melphalan across the murine solid tumor panel, which consisted of B16 melanoma; colon adenocarcinomas 11a, 26, and 36; and the KHT sarcoma.
"
Related Drugs and Biologics
1.
Melphalan (Alkeran)
2.
Therapeutic Uses
3.
Vincristine (Oncovin)
4.
Methotrexate (Mexate)
5.
Fluorouracil (Carac)
6.
Doxorubicin (Adriamycin)
7.
Cytarabine (Cytosar-U)
8.
Cyclophosphamide (Cytoxan)
9.
Cisplatin (Platino)
10.
Carmustine (FIVB)